Why is fair value unavailable for LadRx Corp (OTC-LADX) stock?

A reliable fair value estimate is not currently available for LadRx Corp (OTC-LADX). This generally means the latest dataset does not contain enough valid inputs for the valuation models supported by PriceToWorth. The site does not substitute zero or publish an unsupported estimate; availability may change when updated financial data or applicable model inputs become available.

How is the financial health of LadRx Corp?

The current financial health read for LadRx Corp (OTC-LADX) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is LadRx Corp's next earnings date?

The next earnings date currently listed for LadRx Corp (OTC-LADX) is November 13, 2026.

Does LadRx Corp (OTC-LADX) pay dividends?

The latest available data indicates no current dividend yield for LadRx Corp (OTC-LADX).

What is the market capitalization of LadRx Corp?

The current market capitalization listed for LadRx Corp is 5.446 K.

What is the ticker symbol for LadRx Corp?

The ticker symbol for LadRx Corp is OTC-LADX, and the stock is listed on OTC Markets.

Where is LadRx Corp (OTC-LADX) listed?

LadRx Corp (OTC-LADX) is listed on OTC Markets.

LadRx Corp (LADX) Fair Value & Stock Analysis

LadRx Corp (LADX)

LadRx Corp is a biotechnology company focused on research and development of chemotherapeutic drugs for solid tumors in the United States. The company’s work is centered on its linker activated drug releases, or LADR, platform, which uses an organic backbone attached to a chemotoxic agent designed to target tumor tissue and release the agent within the tumor environment. Its development portfolio includes lead candidates LADRs 7, 8, 9, and 10, which incorporate novel auristatin and maytansinoid derivatives, as well as aldoxorubicin, a program in phase II clinical development for pancreatic cancer. LadRx also develops an albumin companion diagnostic, ACDx, intended to identify patients with cancer who may benefit from treatment with the four lead LADR candidates. The company, formerly known as CytRx Corporation, adopted the LadRx Corporation name in September 2022 and is headquartered in Los Angeles, California.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Analyst Price Target	Analyst Target Upside/Downside	Overall Financial Health	Dividend Yield	Next Earnings Date	Market Cap
OTC-LADX	Not available	Not available	Not available	Weak	0.0%	November 13, 2026	5.446 K